BIOTECH SUMMIT BY THE LAKE

March 27, 2019 • Northwestern University • Evanston, IL

Oppenheimer & Co.
and
Chemistry of Life Processes Institute

Kellogg School of Management
Global Hub, White Auditorium
7:45 AM – 5:30 PM

#biotechbythelake

@CLP_Institute
@OppenheimerCo
SCHEDULE

07:45 a.m.  CONTINENTAL BREAKFAST

08:20 a.m.  Welcome:  Jay Walsh, PhD, Vice President for Research, Northwestern University

08:25 a.m.  Opening Remarks:  Thomas V. O’Halloran, PhD, Founding Director, Chemistry of Life Processes Institute, Northwestern University

Northwestern/CLP Faculty Member Presentations:

08:35 a.m.  Richard B. Silverman, PhD: “Hepatocellular Carcinoma and ALS: Serious Diseases Being Addressed in the Silverman Group”

9:05 a.m.  Evan Scott, PhD: “A Scalable Platform for Enhanced Delivery and Efficacy of Diverse Therapeutic and Diagnostic Agents”

9:35 a.m.  Teresa K. Woodruff, PhD: “Oncofertility: From Bench to Bedside to Babies”

10:05 a.m.  BREAK

10:30 a.m.  Vadim Backman, PhD: “Developing Novel Strategies for Chromatin Regulation to Fight Resistance in Cancer Chemotherapy”

11:00 a.m.  Susan E. Quaggin, MD: “A High ‘TEK’ Solution for Vascular Diseases”

11:30 a.m.  Douglas E. Vaughan, MD: “Targeting PAI-1: A Novel Approach to Delay the Multimorbidity of Aging”
Noon       LUNCH | PANEL DISCUSSION

Moderators:
Jay Olson, CFA, Research Analyst, Oppenheimer & Co.
Silvan Tuerkcan, PhD, Director, Oppenheimer & Co.

Panelists:
Margarita Chavez, JD, Managing Director, AbbVie Ventures
Michael Margolis, R Ph, Managing Director, Oppenheimer & Co.
Jim Sullivan, PhD, Venture Partner, OrbiMed
S. Edward Torres, Founder and Managing Director, Lilly Ventures

Corporate Presentations:

1:00 p.m.   Sujal A. Shah (McC’95 McC’97), President and CEO, CymaBay Therapeutics (CBAY)
1:30 p.m.   Andrew Chan, MD, PhD (WCAS’80), Senior Vice President, Research Biology, Genentech (RHHBY)
2:00 p.m.   Tassos E. Gianakakos (TGS’96), Chief Executive Officer, MyoKardia (MYOK)
2:30 p.m.   BREAK/SNACK
3:00 p.m.   Brian Bernick, MD, FACOG (WCAS ’91), Co-Founder and Director, TherapeuticsMD (TXMD)
3:30 p.m.   Ankit Mahadevia, MD (WCAS’01), President and CEO, Spero Therapeutics (SPRO)
4:00 p.m.   Chandler D. Robinson, MD (WCAS’06), Co-Founder and CEO, Monopar Therapeutics
4:30 p.m.   NETWORKING RECEPTION
5:30 p.m.   EVENT CONCLUDES
Joseph (Jay) Walsh, PhD
Vice President for Research, Northwestern University

As Northwestern University’s Vice President for Research since 2007, Jay Walsh oversees a multifaceted administrative team responsible for supporting the institutional research ecosystem. He also directs the development and implementation of University-wide, research-related strategic plans through leadership support for programs including the Energy Frontier Research Centers (EFRCs); the UI Labs consortium and national hub for digital manufacturing; and the Northwestern-Argonne Institute of Science and Engineering (NAISE). Under Walsh’s leadership, the Northwestern RESEARCH team has made significant contributions to the development and support of Northwestern’s core research facilities and the 50+ University Research Institutes and Centers, including the Institute for Policy Research, the Buffett Institute for Global Studies, the Chemistry of Life Processes Institute, the International Institute for Nanotechnology, and the Institute for Sustainability and Energy at Northwestern. Additionally, Walsh has championed global impact programs, such as the Mandela Washington Fellowship-Young African Leadership Initiative and the program on Equality Development and Global Studies.

Walsh joined Northwestern in 1988 as a professor of biomedical engineering at the McCormick School of Engineering and Applied Sciences, where he later served as associate dean for graduate studies and then senior associate dean. He earned his bachelor’s and master’s degrees in electrical engineering from the Massachusetts Institute of Technology and a doctorate degree in medical engineering from Harvard Medical School. Walsh’s early research on laser-tissue interactions has framed understanding of laser ablation and the scientific foundation for today’s standard laser-based procedures in medicine and surgery. More recently, his research has focused on the diagnostic and therapeutic applications of light.

Walsh has contributed his insights and leadership beyond Northwestern, too. He serves on the Board of Directors at Current and at the Chicago Council on Science and Technology; the Board of Governors at Argonne National Laboratory; the Secretary of the Navy Advisory Panel, the Naval Research Advisory Committee; and the MIT Corporation Visiting Committee for Sponsored Research.
Thomas V. O’Halloran, PhD (Moderator)
*Founding Director, Chemistry of Life Processes Institute*
Charles E. and Emma H. Morrison Professor, Departments of Chemistry and Molecular Biosciences, Weinberg College of Arts and Sciences, Professor of Medicine, Feinberg School of Medicine

Thomas V. O’Halloran is an expert on how living cells sense, regulate and manage metals such as iron, zinc and copper. In addition to showing that changes in the levels of some metals within cells may play a role in infectious diseases, cancer, liver disorders and diabetes, he has developed novel drugs for diseases such as Wilson’s disease, fungal infections and cancer. His work also offers insights into the effect of zinc on the reproductive process and has led to the creation of new therapies that harness the biological chemistry of metals such as arsenic and platinum.

O’Halloran is the Charles E. and Emma H. Morrison Professor in Chemistry and Professor of Molecular Biosciences in the Weinberg College of Arts and Sciences and a professor in the department of medicine, division of hematology and oncology in the Feinberg School of Medicine. He is the founding director of the Chemistry of Life Processes Institute (CLP) and director of the Institute’s Quantitative Bio-element Imaging Center and Center for Developmental Therapeutics. O’Halloran is the principal investigator of the Chicago Region Physical Science-Oncology Center (CR-PSOC), a partnership between CLP and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University that unites physical scientists and cancer researchers from Northwestern, the University of Chicago and the University of Illinois at Chicago.
“Hepatocellular Carcinoma and ALS: Serious Diseases Being Addressed in the Silverman Group”

Richard B. Silverman, PhD
Resident Member, Chemistry of Life Processes Institute
Patrick G. Ryan/Aon Professor
Professor of Chemistry and Professor of Molecular Biosciences, Weinberg College of Arts and Sciences

Richard B. Silverman is the inaugural Patrick G. Ryan/Aon Professor. Over the last 42 years at Northwestern University he has developed numerous projects related to the synthesis and evaluation of a variety of enzyme inhibitors and activators, particularly related to neurodegenerative and neurological diseases and cancer. One of the projects was very successful: he is the inventor of Lyrica™, a blockbuster drug marketed by Pfizer for epilepsy, fibromyalgia, and neuropathic pain. Silverman currently has a GABA aminotransferase inactivator (CPP-115) that completed a Phase I clinical trial showing no adverse effects; inhibitors of protein aggregation and toxicity from mutant SOD1 that are active in an ALS mouse model; inactivators of ornithine aminotransferase for hepatocellular carcinoma; selective inhibitors of neuronal nitric oxide synthase (nNOS) that are undergoing preclinical studies for cerebral palsy; novel antagonists for the CaV1.3 pore of a calcium channel targeted for Parkinson’s disease; and compounds for use in enzyme replacement therapy for Gaucher’s disease. Several inhibitors of nNOS have also been found to be active against melanoma and others, in combination with antibiotics, as antibacterial agents.

Silverman is the author or co-author of over 370 publications and holds 100 patents to date. The third edition of his textbook, The Organic Chemistry of Drug Design and Drug Action, was published by Elsevier/Academic Press in 2014. He has received many awards, including the Creative Invention Award of the American Chemical Society (ACS) 2017; Fellow, National Academy of Inventors 2014; Fellow, American Academy of Arts & Sciences 2014; Northwestern University Trustee Medal for Faculty Innovation and Entrepreneurship 2014; Medicinal Chemistry Prize of the Israel Chemical Society 2014; and Fellow, Royal Society of Chemistry 2013.
“A Scalable Platform for Enhanced Delivery and Efficacy of Diverse Therapeutic and Diagnostic Agents”

Evan A. Scott, PhD  
*Resident Member, Chemistry of Life Processes Institute*  
Assistant Professor of Biomedical Engineering;  
McCormick School of Engineering

Evan Scott has been an Assistant Professor of Biomedical Engineering at Northwestern University since the fall of 2013. He respectively received a BS and PhD in Biomedical Engineering from Brown University in 2002 and Washington University in St. Louis in 2009. His dissertation work was performed in the laboratory of Professor Donald Elbert, where he developed methods based in proteomics and polymer chemistry to both analyze and control the interactions between cells and material surfaces. As a Whitaker International Scholar, he spent four years in Switzerland at the EPFL performing postdoctoral research in the laboratories of Professor Jeffrey Hubbell and Professor Melody Swartz. There he investigated new formulations and strategies for both HIV vaccination and cancer immunotherapy.

Scott is a recipient of the 2015 NIH Director’s New Innovator Award, the 2015 National Science Foundation CAREER Award and the 2014 American Heart Association Scientist Development Grant. His laboratory is focused on the development of bioresponsive soft nanomaterials for diverse applications in controlled drug delivery. Current disease models include atherosclerosis, tuberculosis & neonatal vaccination, cancer immunotherapy, transplant tolerance and Chagas disease.
FACULTY PRESENTATIONS

“Oncofertility: From Bench to Bedside to Babies”

Teresa K. Woodruff, PhD
Member, Chemistry of Life Processes Institute
Thomas J. Watkins Professor of Obstetrics and Gynecology and Dean, The Graduate School

Teresa K. Woodruff is Dean of The Graduate School and Associate Provost for Graduate Education at Northwestern University. She is the Thomas J. Watkins Professor of Obstetrics & Gynecology, the Vice Chair for Research, and Chief of the Division of Reproductive Science in Medicine in the Department of Obstetrics & Gynecology, Feinberg School of Medicine. She holds joint faculty appointments as Professor of Molecular Biosciences in Weinberg College of Arts & Sciences, Professor of Biomedical Engineering in McCormick School of Engineering, and Professor of Medical Social Sciences in Feinberg School of Medicine.

Woodruff is an internationally recognized expert in ovarian biology and reproductive science. In 2006, she coined the term “oncofertility” to describe the merging of two fields: oncology and fertility. In addition, she championed the new National Institutes of Health (NIH) policy mandating the use of females in fundamental research. She is Director of the Center for Reproductive Science (CRS), Founder and Co-Director of the Women’s Health Research Institute (WHRI), and Director of the Oncofertility Consortium. She is past president of the Endocrine Society and current Editor-in-Chief of Endocrinology.

As a leading research scientist, Woodruff was awarded the Presidential Award for Excellence in Science Mentoring by President Obama in an oval office ceremony in 2011. She holds 14 U.S. Patents and is an elected fellow of the National Academy of Medicine (2018), the National Academy of Inventors (2018), the American Institute for Medical and Biomedical Engineers (2017), and the American Association for the Advancement of Science (2005).

BREAK
“Developing Novel Strategies for Chromatin Regulation to Fight Resistance in Cancer Chemotherapy”

Vadim Backman, PhD
Resident Member, Chemistry of Life Processes Institute
Walter Dill Scott Professor of Biomedical Engineering, McCormick School of Engineering; Professor, Biochemistry and Molecular Genetics, Feinberg School of Medicine

Vadim Backman, PhD, is the Walter Dill Scott Professor of Biomedical Engineering at the McCormick School of Engineering and Applied Sciences, Professor of Medicine (Hematology/Oncology) and Professor of Biochemistry and Molecular Genetics at the Feinberg School of Medicine at Northwestern University and Program Leader in Cancer and Physical Sciences at the Robert H. Lurie Comprehensive Cancer Center. He received his PhD in Medical Engineering from Harvard University and the Massachusetts Institute of Technology.

Backman’s research is focused on bridging advances in biophotonics into biomedical research and clinical medicine. He develops novel super-resolution optical technologies for characterization and imaging of biological tissue with a focus on the nanoscale and molecular levels. His research spans from cancer biophysics to novel optical diagnostic and imaging techniques to novel therapeutics and multi-center clinical trials. Backman has received numerous awards including being selected as one of the top 100 young innovators in the world by the MIT Technology Review Magazine, the Cozzarelli Prize from the National Academy of Sciences, and has served on multiple NIH and NSF review panels, as well as chair of various scientific conferences such as OSA Biomed and SPIE Biomedical Applications of Light Scattering.

He has published more than 215 papers in peer-reviewed journals including Nature, Nature Medicine, PNAS, and Physical Review Letters and holds over 20 patents. In the past three years, he has served as the principle investigator on more than 20 grants from the National Institutes of Health and National Science Foundation, including an NIH Bioengineering Research Partnership. At Northwestern, he teaches advanced classes in optics and human physiology. Backman is the co-founder of three biotech companies.
“A High ‘TEK’ Solution for Vascular Diseases”

**Susan E. Quaggin, MD**  
*Member, Chemistry of Life Processes Institute*  
Charles H. Mayo, MD, Professor of Medicine; Director, Feinberg Cardiovascular and Renal Research Institute; Chief, Nephrology and Hypertension, Department of Medicine, Feinberg School of Medicine

Susan E. Quaggin, MD, FASN, is a graduate of the University of Toronto where she completed her residency and served as chief medical resident for the University’s St. Michael’s Hospital. She completed her nephrology fellowship at the University of Toronto and Yale University, where she also completed research and post-doctoral training. Quaggin also trained in the developmental biology program at the University of Toronto’s Samuel Lunenfeld Research Institute.

Quaggin’s research interests include a focus on fundamental genetic pathways required to establish and maintain the integrity of the specialized vascular beds in the kidney and eye. To understand and identify new therapeutic targets, she’s worked to develop numerous genetic mouse models that allow cell and time-specific manipulation of functional genes. Translation of her group’s findings regarding the vasculature reveals pathogenic mechanisms and new therapeutic targets for a number of diseases, including diabetic nephropathy and retinopathy, nephrotic syndrome, and glaucoma.

Currently she is the Charles Horace Mayo professor of medicine at Northwestern University where she serves as the Chief of the Division of Nephrology & Hypertension and the Director of the Feinberg Cardiovascular and Renal Research Inst. Quaggin was elected to the American Society for Clinical Investigation in 2006 and the Association of American Physicians in 2013 and is a member of the External Scientific Panel of Astra Zeneca and CSO of Mannin Research. She currently serves as a councilor and future President of the American Society of Nephrology and Chair of the PBKD NIH Study Section.
“Targeting PAI-1: A Novel Approach to Delay the Multi-morbidity of Aging”

Douglas E. Vaughan, MD

*Member, Chemistry of Life Processes Institute*

Chair, Department of Medicine; Irving S. Cutter Professor of Medicine; Professor of Medicine (Cardiology), Feinberg School of Medicine

Douglas Vaughan, MD, is Irving S. Cutter Professor and Chairman of the Department of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, IL. He received his MD from the University of Texas Southwestern Medical School in Dallas and completed his internship and residency in Internal Medicine at Parkland Memorial Hospital/Veterans Administration Medical Center, also in Dallas. He completed his fellowship in Cardiology at Brigham and Women’s Hospital and Harvard Medical School in Boston, MA. He is a fellow of the American College of Cardiology, and has been elected to membership in the American Society for Clinical Investigation and the Association of American Physicians.

As a Principal Clinical Investigator, Vaughan’s work spans the bench to the bedside. His efforts and findings in vascular biology include basic investigations into regulation of gene expression, genetic models of disease, mechanistic studies in humans, and clinical trials. His primary research interests are in the mammalian plasminogen activator system and the role this system plays in cardiovascular disease and physiological aging.
Jay Olson, CFA (Co-Moderator)
Research Analyst
**Oppenheimer & Co.**

Jay Olson is Managing Director and Senior Analyst covering Biotechnology since 2016. Prior to joining Oppenheimer, Olson covered SMID-cap names and worked on the Large Cap Pharmaceuticals team at Goldman Sachs for 4 years after 4 years on the #1 II-ranked Large Cap Pharmaceuticals team at Sanford Bernstein. Prior to Wall Street, Olson spent 18 years in the pharmaceutical industry, working mostly for Pfizer in finance, marketing and business development. Olson received an MBA in Finance and an MS in Chemical Engineering both from MIT, and a BS in Chemical Engineering from Tufts University. He also holds the CFA designation.

Silvan Tuerkcan, PhD (Co-Moderator)
Director
**Oppenheimer & Co.**

Silvan Tuerkcan is Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, Tuerkcan worked on the Large Cap Pharmaceuticals team at Goldman Sachs. Prior to Wall Street, he spent 5 years in research, working at the Stanford University School of Medicine and the Pasteur Institute focusing on imaging technologies in oncology. Tuerkcan holds a BS in Physics from McGill University, a MS in Engineering Physics from TU Munich, and a PhD in Biophysics from Ecole Polytechnique (France). Tuerkcan co-authored 22 peer-review articles and holds three patents.

Margarita Chavez, JD
Managing Director
**AbbVie Ventures**

Margarita Chavez is Managing Director at AbbVie Ventures. Chavez has lead investments in over a dozen biotech companies in the US and Europe and is responsible for AbbVie’s investments in Alector, Morphic Therapeutics, Palleon Pharmaceuticals, eFFECTOR Therapeutics, CARISMA Therapeutics, Jnana Therapeutics and Magnolia Neurosciences. Chavez brings over 20 years of deal making experience, with over a decade in biotech M&A, licensing, and venture. Chavez was previously a Director with Abbott's Global Pharmaceutical Licensing & Acquisitions. Among others, she was involved in the in-licensing of Elagolix, the acquisition of Immuvuen, and the acquisition of the Lupron franchise. Before joining Abbott, Chavez practiced as a corporate and securities lawyer in Silicon Valley with the firm of Brobeck Phleger & Harrison, advising in equity financings, M&A and IPOs. Chavez currently serves on the Boards of the New England Venture Capital Association and the MidAmerica Healthcare Investors Network and on the Advisory Board of the Santa Clara University School of Law.
Michael A. Margolis R Ph
Managing Director
Oppenheimer & Co.

Michael Margolis joined Oppenheimer & Co. Inc. in 2017 where he currently serves as Co-Head of Healthcare Investment Banking. He has over two decades of Investment Banking experience in the Life Sciences sectors. Prior to joining Oppenheimer, Margolis served as the Head of Healthcare Investment Banking at Roth Capital Partners, LLC, and as a Managing Director at Merriman Holdings, Inc. (also known as Merriman Curhan Ford Group Inc.). Before becoming an Investment Banker, Margolis worked at Novartis Pharmaceuticals Corporation in several roles and at Ursus Capital. He began his career at Eli Lilly & Company as a Senior Pharmaceutical Representative. Margolis is a registered Pharmacist and holds an MBA from New York University’s Stern School of Business and a Pharmacy Degree from Rutgers University, College of Pharmacy.

Jim Sullivan, PhD
Venture Partner
OrbiMed

Jim Sullivan is a Venture Partner with OrbiMed. Previously, Sullivan was the Vice President of Discovery at AbbVie, responsible for AbbVie’s research efforts in a variety of therapeutic/disease areas including oncology, immunology, neurology, hepatitis C and cystic fibrosis. Sullivan has advanced more than 100 compounds into clinical development across a number of disease states and technology platforms. He has authored/co-authored more than 130 scientific publications and is an inventor on 11 patents. Sullivan is an adjunct faculty member at Northwestern University and serves on the board of a number of companies and foundations. He earned his bachelor’s degree and PhD in biochemistry from Trinity College in Dublin, Ireland, and conducted post-doctoral research in neurobiology at Northwestern University.

S. Edward Torres
Founder and Managing Director
Lilly Ventures

Edward Torres oversees Lilly Ventures, a venture capital firm investing in start-up life science companies developing novel, potentially life-altering medicines and technologies. He brings three decades of pharmaceutical and venture capital experience to the team. Since co-founding Lilly Ventures in late 2001, he has led the investments in, and served on the boards of, several biotech companies including the Fund’s successful exits of Receptos, Coherus, Viamet, Conforma and Serenex. Torres also serves on several social services non-profit boards and advisory boards. Prior to his role in Lilly Ventures, Torres had a diverse set of experiences throughout the domestic and international pharmaceutical businesses including operational finance, planning, M&A, business development, and global marketing roles. Torres received a Bachelor of Arts from Creighton University and a Master of Business Administration from the University of Michigan’s Ross School of Business, where he was a Consortium Fellow.
Sujal Shah (McC’95 McC’97)
President and Chief Executive Officer
CymaBay Therapeutics (CBAY)

Sujal Shah has served as President and Chief Executive Officer, CymaBay Therapeutics, since March 2017. Previously, he served as Chief Financial Officer since December of 2013. Prior to that, Shah served as a consultant and acting Chief Financial Officer for CymaBay from June 2012 to December 2013. From 2010 to 2012, he served as Director, Health Care Investment Banking for Citigroup Inc., where he was responsible for managing client relationships and executing strategic and financing related transactions for clients focused in life sciences. From 2004 to 2010, Shah was employed with Credit-Suisse, last serving in the capacity as Vice President, Health Care Investment Banking Group. He currently serves on the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University. Shah received a MBA from Carnegie Mellon University Tepper School of Business and MS and BS degrees in Biomedical Engineering from Northwestern University.

Andrew Chan, MD, PhD (WCAS’80)
Senior Vice President, Research Biology
Genentech (RHHBY)

Andrew C. Chan, MD, serves as Senior Vice President of Research Biology at Genentech, Inc. Previously, he served as Senior Vice President of Immunology at Genentech Inc. Chan was responsible for overseeing research programs focused on the role of the immune system in cancer and various immunological disorders. He served as Vice President, Research-Immunology of Genentech, Inc. since July 17, 2003. He continued to supervise Genentech’s immunology research program for the treatment of immune-mediated and inflammatory disorders. Chan’s laboratory is currently working on defining the role of B-cells in autoimmune disease and understanding the mechanisms of action of anti-CD20 and other B-cell modulatory therapies. Chan joined Genentech, Inc. in 2001 as senior Director of Immunology in the Research department.

Chan holds a Bachelor’s and Master’s degrees in chemistry from Northwestern University and a Medical Degree and Doctorate in cellular and developmental biology from the Washington University School of Medicine in St. Louis. He completed his internship and residency in internal medicine at Barnes Hospital at Washington University School of Medicine before becoming a postdoctoral clinical, and research fellow at the University of California, San Francisco. Prior to joining Genentech, Chan was an associate professor in the Division of Rheumatology and the Departments of Medicine, Pathology and Immunology at Washington University School of Medicine in St. Louis, where he was also a Howard Hughes Medical Institute (HHMI) associate investigator. Chan is a frequent lecturer and has authored or co-authored more than 50 scientific articles.
Tassos E. Gianakakos (TGS’96)
Chief Executive Officer
MyoKardia (MYOK)

Tassos Gianakakos joined MyoKardia in October 2013, bringing more than 17 years of senior leadership experience and business development and finance expertise in the biopharmaceutical industry to the company. He joined MyoKardia from MAP Pharmaceuticals (acquired by Allergan in March 2013), where he was most recently senior vice president and chief business officer. In this position, Gianakakos played an integral role in advancing the company’s two Phase 3 clinical programs and regulatory filings for LEVADEX®, and led the successful co-promotion partnership agreement for the program with Allergan, as well as a global partnership with AstraZeneca for the company’s Unit Dose Budesonide program.

Prior to MAP, Gianakakos led the formation of Codexis, Inc., a spin-off of Maxygen, Inc., in 2001. At Codexis, Gianakakos served as president and senior vice president, business development, and global head of Codexis’ Pharmaceuticals Business Unit. Before forming Codexis, Gianakakos was director of business development at Maxygen, where he led the company’s business development efforts for its vaccine and bio-industrial platforms, as well as financing activities including the company’s initial public offering. Prior to Maxygen, Gianakakos was a process engineer in Merck & Co.’s vaccine division.

Gianakakos holds BSc degrees in chemical engineering and economics from the Massachusetts Institute of Technology, an MSc in biotechnology from Northwestern University and an MBA from Harvard Business School.
Brian Bernick, MD, FACOG (WCAS ’91)
Co-Founder and Director
TherapeuticsMD (TXMD)

Brian Bernick, MD, FACOG, is a graduate of Northwestern’s Weinberg College of Arts and Sciences, class of 1991 where he was pre-med and earned a degree in economics. Bernick went on to specialize in obstetrics and gynecology, completing his residency through the University of Pennsylvania. Thereafter, Bernick has spent the last 20 years in private practice in Boca Raton, Florida. During that time, he served as the Chairman of the Department of Obstetrics and Gynecology at Boca Raton Regional Hospital and as an associate professor at Florida Atlantic University College of Medicine.

In 2008, Bernick founded TherapeuticsMD a woman’s healthcare company that over the last three years has obtained 3 new drug approvals. TherapeuticsMD is a NASDAQ traded company with an estimated market cap of $1.4B. Bernick is the recipient of several national and regional awards, including recognition by his peers as one of the top doctor’s in his specialty. Bernick has over 100 peer-reviewed publications and presentations of original research at medical conferences. Bernick holds 21 US and 24 foreign patents focusing on drug therapies and analysis.

Ankit Mahadevia, MD (WCAS’01)
President and Chief Executive Officer
Spero Therapeutics (SPRO)

Ankit Mahadevia is the CEO of Spero Therapeutics and a member of the Board of Directors. He was formerly a Venture Partner in the life sciences group at Atlas Venture, located in Cambridge, MA. In that capacity he supported the formation of eight companies focused on novel drug discovery platforms and therapeutic products, three of which he led as Acting CEO.

Chandler D. Robinson, MD (WCAS’06)
Co-Founder and Chief Executive Officer
Monopar Therapeutics

Chandler D. Robinson, MD, co-founded Monopar Therapeutics LLC in 2010 and has been its Chief Executive Officer and Director since December 2014. Among his previous experiences, Robinson in 2008 worked at Onyx Pharmaceuticals in their Nexavar marketing division; from 2008-2009 as a co-manager of a healthcare clinic in San Jose CA; from 2004 to present as Founder and President of an undergraduate research focused non-profit; and from 2006 to 2007 at Bear Stearns investment bank. He was previously on the board of Wilson Therapeutics and is currently on the board of Northwestern University’s Chemistry of Life Processes Institute. Robinson graduated summa cum laude from Northwestern University, earned a master’s degree in International Health Policy and Health Economics from the London School of Economics on a Fulbright Scholarship, an MBA from Cambridge University on a Gates Scholarship and an MD from Stanford University.

Robinson graduated summa cum laude from Northwestern University, earned a master’s degree in International Health Policy and Health Economics from the London School of Economics on a Fulbright Scholarship, an MBA from Cambridge University on a Gates Scholarship and an MD from Stanford University.

NETWORKING RECEPTION | 4:30 p.m.

EVENT CONCLUDES | 5:30 p.m.
SUPPORTED BY

Center for Developmental Therapeutics
The Center for Developmental Therapeutics (CDT), managed and operated by Chemistry of Life Processes Institute, was established to rapidly and efficiently advance novel therapeutic interventions from basic research to the clinic. The CDT is one of the first academic-based drug development centers that bridges all aspects of translational research in a single entity including early drug discovery, mechanistic research, pre-clinical development and translation into the clinic.
cdt.northwestern.edu

Innovation and New Ventures Office (INVO)
INVO catalyzes the translation of Northwestern innovations to benefit the public and promote economic growth. INVO works with faculty and students across the Chicago and Evanston campuses, as well as partners at Lurie Children’s Hospital, Northwestern Memorial Hospital and the AbilityLab, to create startups and partnerships with corporations. By fostering innovation and commercialization, INVO strives to improve quality of life and fuel economic growth.
invo.northwestern.edu

Northwestern Corporate Engagement
Northwestern University’s Corporate Engagement Office serves as the central point of contact to the University for all corporate and industry partners. The office connects partners across campuses and disciplines by strengthening existing and new relationships.
corporate.northwestern.edu
About Chemistry of Life Processes Institute
Chemistry of Life Processes Institute is where new cures and better diagnostics for life-threatening diseases begin. Drawn by the Institute's extraordinary expertise and facilities for innovation and translation, researchers from across Northwestern University converge here to develop fresh insights and approaches for treating and diagnosing complex diseases like cancer, epilepsy, heart disease, and Parkinson's. Together, we accelerate the delivery of revolutionary science that improves lives and transforms human health.

clp.northwestern.edu

About Oppenheimer & Co. Inc.
For more than 130 years, Oppenheimer & Co. Inc. has provided our clients with the financial expertise and insight to help achieve their goals. Oppenheimer's proud tradition of providing innovative, customized solutions to our clients sets us apart from our competitors. We believe in independent thinking that leads to innovative strategies tailored to the needs of our clients.

Op Beauheimer is proud of its reputation as a Firm that helps individuals, families, corporate executives, foundations and endowments, charities, pension plans, businesses, and institutions.

oppenheimer.com